Pharma giant Teva promises to create over 800 jobs in N.J. Are they worth $40M? - nj.com
Teva's Turnaround: Is It Ever Or Never?
Reflecting on a Year of Remarkable Achievements and Resilience at Teva Pharmaceuticals
Teva down as it reports lower sales and profit for 2018
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies - 340B Report
Teva selects North Jersey site for its new North American headquarters. - Philadelphia Business Journal
Teva Pharmaceutical Industries (NASDAQ:TEVA) Share Price | RNS News, Quotes, & Charts | TEVA
Here's Why Teva Pharma Stock Is Soaring Today
Teva Pharmaceutical Shares Plunge After Quarterly Loss and 2018 Outlook Warning - WSJ
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug Ajovy | BioSpace
Teva Pharmaceutical Industries Limited 2018 Q4 - Results - Earnings Call Slides (NYSE:TEVA) | Seeking Alpha
A Deep Dive into Teva Pharma Financials Shows Significant Weakness and Optimism | BioSpace
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Lured by $40 million tax break, Teva moving U.S. headquarters from Pa. to North Jersey - WHYY
Teva | Partnership | Direct Relief
Teva Pharmaceuticals in peer group American glamour stocks | Valuespectrum.com
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva Says 2018 Profit Will Keep Falling as Generic Drug Slump Persists - Bloomberg
Teva Pharmaceuticals soars after Warren Buffett's Berkshire Hathaway discloses a stake (TEVA) | Markets Insider
Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record
Battered by a Tough Generics Market, Teva Pharma Emphasizes Biologics | BioSpace
Closure of another criminal case will help Teva's new CEO to focus on return to growt | Ctech
FDA approves Teva's generic EpiPen after yearslong delay
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
Teva Reports Massive $11.6 Billion Loss, Predicts Weak 2018 - Business - Haaretz.com
